53929-59-2

Basic information

• Product Name: 4-METHYL-PYRIDINE-2,3-DIAMINE
• Synonyms: 4-METHYL-PYRIDINE-2,3-DIAMINE;4-methyl-2,3-pyridinediamine(SALTDATA: FREE);2,3-diaMino-4-Methylpyridine;4-Methyl-2,3-pyridinediaMine;4-Methyl-2,3-diaminopyridine;NSC 249323;2,3-PyridinediaMine, 4-Methyl-
• CAS NO: 53929-59-2
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.16
• EINECS: -0
• Mol File: 53929-59-2.mol
• Article Data: 18

Chemical Properties

• Melting Point: 115-116℃
• Boiling Point: 317.8 °C at 760 mmHg
• Flash Point: 171.9 °C
• Appearance: /
• Density: 1.19 g/cm³
• Vapor Pressure: 0.000377mmHg at 25°C
• Refractive Index: 1.647
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.35±0.47(Predicted)
• CAS DataBase Reference: 4-METHYL-PYRIDINE-2,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-PYRIDINE-2,3-DIAMINE(53929-59-2)
• EPA Substance Registry System: 4-METHYL-PYRIDINE-2,3-DIAMINE(53929-59-2)

Safety Data

• Hazardous Substances Data: 53929-59-2(Hazardous Substances Data)

Usage

General Description

4-Methyl-Pyridine-2,3-Diamine, also known as 4-Methyl-2,3-diaminopyridine, is an organic compound primarily used in the synthesis of other chemicals. It consists of a pyridine ring, which is a basic six-membered ring with two nitrogen atoms, and is substituted with a methyl group and two amino groups. This structure allows for interesting reactivity and bonding patterns. This chemical is sensitive to air and light and is often stored in an inert atmosphere. As with many chemical compounds, it requires careful handling due to its potential health hazards, such as skin and eye irritation or harm if inhaled or swallowed.

InChI:InChI=1/C6H9N3/c1-4-2-3-9-6(8)5(4)7/h2-3H,7H2,1H3,(H2,8,9)

Upstream product

• 6635-86-5 2-amino-4-methyl-3-nitropyridine 
• 100114-04-3 3-Amino-4-methyl-pyridin-1-oxid 
• 1038919-62-8 4-methyl-2-nitropyridin-3-amine 

Downstream Products

• 133240-38-7 L 158338 
• 577777-13-0 [7-methyl-2-(3H-imidazo[4,5-b]pyridine)-2-yl]acetonitrile 
• 133240-16-1 2-Isopropyl-7-methylimidazo[4,5-b]pyridine 
• 115951-60-5 2,7-Dimethylimidazo<4,5-b>pyridine 
• 845960-13-6 2-(4-fluorophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 
• 1274481-63-8 C₁₄H₁₃N₃O 
• 1274808-28-4 C₁₃H₁₀ClN₃ 
• 1367866-23-6 2-(4-methoxyphenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 
• 944745-89-5 2-(4-chlorophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 
• 944746-01-4 2-(2,4-difluorophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 

Relevant articles and documents

Imidazopyridine- and purine-thioacetamide derivatives: Potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1)

Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) belongs to the family of ecto-nucleotidases, which control extracellular nucleotide, nucleoside, and (di)phosphate levels. To study the (patho)physiological roles of NPP1 potent and selective inhibitors with drug-like properties are required. Therefore, a compound library was screened for NPP1 inhibitors using a colorimetric assay with p-nitrophenyl 5′-thymidine monophosphate (p-Nph-5′-TMP) as an artificial substrate. This led to the discovery of 2-(3H-imidazo[4,5-b]pyridin-2-ylthio)-N-(3,4-dimethoxyphenyl)acetamide (5a) as a hit compound with a Ki value of 217 nM. Subsequent structure-activity relationship studies led to the development of purine and imidazo[4,5-b]pyridine analogues with high inhibitory potency (Ki values of 5.00 nM and 29.6 nM, respectively) when assayed with p-Nph-5′-TMP as a substrate. Surprisingly, the compounds were significantly less potent when tested versus ATP as a substrate, with Ki values in the low micromolar range. A prototypic inhibitor was investigated for its mechanism of inhibition and found to be competitive versus both substrates.

Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3β inhibitors

Design, synthesis and biological evaluation of the imidazopyridine analogs as novel GSK3β inhibitors for treatment of type 2 diabetes mellitus are described. Most of the analogs exhibited excellent inhibitory activities (IC50 44 nM) against glycogen synthase kinase 3β (GSK3β). The structure-activity relationship (SAR) of the imidazopyridine analogs and the binding mode of analog 23 in the catalytic domain of GSK3β, based on our X-ray crystallography study, are described. In particular, analog 28, which was selected as a potential drug candidate for treatment of type 2 diabetes mellitus, exhibited excellent GSK3β inhibition, pharmacokinetic profiles and blood glucose lowering effect in mouse.

COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES

Compounds of following formula (I) are provided that have both angiontensin Il receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the co